Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for rare diseases using its proprietary cell penetrating peptide (CPP) platform. Its lead candidate, nomlabofusp, targets Friedreich's ataxia (FA) by delivering frataxin protein intracellularly and has received multiple expedited regulatory designations including FDA Breakthrough Therapy status. The company plans a Biologics License Application (BLA) submission targeted for mid-2026 alongside a global Phase 3 confirmatory trial. Larimar reported operating losses of $172.5 million in 2025 with no revenues to date [F1], driven by intensifying R&D and clinical development costs. At year-end 2025, Larimar held $85.4 million in cash plus proceeds from a February 2026 public offering expected to fund operations into Q2 2027 [F1][N2]. Manufacturing is outsourced under cGMP standards, presenting scale-up risks, while competition includes established and emerging players addressing FA and related indications [S24].